Metabolic Connections: Rethinking MASLD, MASH, and Obesity in an Evolving Management Landscape

Evidence increasingly highlights the overlapping prevalence and shared pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), obesity, and other cardiometabolic conditions, yet the interconnected nature of these diseases is often underrecognized in patient care. Guideline-recommended screening for MASLD remains low among patients at increased risk, such as those with obesity, and many adults with MASLD are unaware of their condition. At the same time, rapidly evolving evidence, guidelines, and treatment options are expanding opportunities to address obesity and related conditions while creating new challenges for clinicians in providing integrated care. A clear understanding of the links among obesity, MASLD/MASH, and cardiometabolic disease, along with the role of treatments targeting weight loss in improving metabolic health, is essential for optimal patient care. Focusing on small-group, case-based discussions and real-time expert feedback, this symposium will equip healthcare professionals to consider underlying pathophysiology, apply screening and risk-stratification strategies, and translate emerging evidence into practice as they develop individualized, comprehensive care plans that support liver and overall cardiometabolic health.

Supported by; Boehringer Ingelheim Pharmaceuticals, Inc.
Organized by: Clinical Care Options, LLC dba Decera Clinical Education
CE: 1.5 CME Hours